Deutsche Bank’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
Deutsche Bank's BDTX Position: Q3 2026 in Review
Deutsche Bank reduced its Black Diamond Therapeutics (BDTX) stake by 13% in Q3 2026, selling an estimated $11.3K and leaving 40,261 shares worth $76.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3423.
Deutsche Bank first reported a position in BDTX in Q1 2020 and has held it in 16 quarters since. The position peaked at $1.42M in Q2 2021. 105 funds tracked by Wall St. Rank hold BDTX as of Q3 2026.
- Deutsche Bank held 40,261 shares of Black Diamond Therapeutics worth $76.1K as of Q3 2026.
- Deutsche Bank sold 5,777 Black Diamond Therapeutics shares in Q3 2026, an estimated $11.3K.
- Black Diamond Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3423 holding.
- Deutsche Bank first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 16 quarters since.
- Deutsche Bank's Black Diamond Therapeutics position peaked at $1.42M in Q2 2021.
- 105 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2026.
Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.